The Relationship between Heme Oxygenase-1 Expression and Response to Cisplatin Containing Chemotherapy in Advanced Non-Small Cell Lung Cancer.
10.4046/trd.2006.60.3.314
- Author:
Doo Kyung YANG
1
;
Mee Sook ROH
;
Kyung Eun LEE
;
Ki Nam KIM
;
Ki Nam LEE
;
Pil Jo CHOI
;
Jung Hee BANG
;
Bo Kyung KIM
;
Hyo Rim SEO
;
Min Ji KIM
;
Seul Ki KIM
;
Soo Keol LEE
;
Choon Hee SON
Author Information
1. Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea. chshon@dau.ac.kr
- Publication Type:Original Article
- Keywords:
Heme oxygenase-1;
Non-small cell lung cancer;
Cisplatin containing chemotherapy
- MeSH:
Carcinoma, Non-Small-Cell Lung*;
Cisplatin*;
Drug Therapy*;
Heme Oxygenase-1*;
Heme*;
Humans;
Medical Records;
Oxidative Stress;
Retrospective Studies
- From:Tuberculosis and Respiratory Diseases
2006;60(3):314-320
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: The overall response (20-30%) to chemotherapy in non-small cell lung cancer (NSCLC) is quite poor. Heme oxygenase-1 (HO-1) is the rate-limiting enzyme in heme degradation. There is increasing evidence suggesting that the induction of HO-1 might have an important protective effect against oxidative stress including cisplatin containing chemotherapy. This study retrospectively investigated the relationship between HO-1 expression and the response to chemotherapy containing cisplatinin advanced NSCLC patients. MATERIAL AND METHODS: The medical records including the responses to chemotherapy of fifty nine cases were evaluated retrospectively, and the tissue samples of these patients were immunohistochemically stained for HO-1. RESULTS: Forty three of the fifty nine patients(72.8%) showed positive staining for HO-1 in their cancer tissues. There was no significant difference according to the cell type, stage and tumor size. In addition, there was no correlation between HO-1 expression and the responses to chemotherapy. CONCLUSION: HO-1 expression in tumor tissue dose not predict the response to cisplatin containing chemotherapy in advanced NSCLC. Further prospective studies with a larger number of patients will be needed to confirm these results.
